Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316408 | 0.91 | POLB (0.47) | POLBCA14KDM4EMAPTTMEM97 | |
| SCHEMBL25942505 | 0.85 | POLB (0.49) | POLBCA14TP53BP1KDM4EMAPT | |
| SCHEMBL23594056 | 0.85 | POLB (0.49) | POLBCA14TP53BP1KDM4EMAPT | |
| SCHEMBL23975102 | 0.83 | MEN1 (0.48) | POLBCA14TP53BP1KDM4EMAPT | |
| SCHEMBL14176540 | 0.81 | CHRM2 (0.35) | CA14 | |
| SCHEMBL23975224 | 0.80 | POLB (0.40) | POLBCA14KDM4EMAPTTMEM97 | |
| SCHEMBL10201764 | 0.80 | DNM1 (0.49) | POLBCA14KDM4EMAPTALDH1A1 | |
| SCHEMBL12438387 | 0.79 | EPHX1 (0.47) | POLBDNM1EPHX1 | |
| SCHEMBL16316406 | 0.79 | POLB (0.42) | POLBCA14KDM4EMAPTALDH1A1 | |
| SCHEMBL25826388 | 0.77 | POLB (0.42) | POLBCA14TP53BP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | HAVCR2, CUL4A, PSMC3 | POLB 2662/4885CA14 4153/4885TP53BP1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.